Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature
Publication

Publications

Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature

Title
Adenosine Receptor Ligands on Cancer Therapy: A Review of Patent Literature
Type
Article in International Scientific Journal
Year
2018
Authors
Sousa, JB
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Diniz, C
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Goncalves, J
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 13
Pages: 40-69
ISSN: 1574-8928
Publisher: Bentham Science
Other information
Authenticus ID: P-00N-KBV
Abstract (EN): Background: Adenosine is a purine, with an adenine group and a ribose sugar, formed endogenously by ATP catabolism both intracellularly and extracellularly. Among the medicinal features of adenosine and its receptors (A(1), A(2A), A(2B) and A(3)), anticancer activity has been an intense field of research. The anticancer potential of adenosine receptor ligands has been brought to the forefront of research and evidenced in innumerous research articles and patents. Objective: The present review focuses on the patent literature from 2002 onwards (2002-May 2017). Methods: Patents were searched and downloaded from the open access patent data bases and are available online. Results: A significant number of patents (65) have been published on adenosine receptor ligands claiming anticancer activity, or presenting new methods of preparation or treatment thereof, from 2002-2017 (May). From these, 35 were published highlighting the promising attributes of compounds/methods to fight cancer. Most of the compounds act as adenosine A(3) receptor agonists, while others act as antagonists for the other adenosine receptor subtypes. The signaling events triggered by activation of adenosine A(3) receptor or by blockade of adenosine A(1), A(2A) and A(2B) receptors can reverse an environment from being pro-cancer to an anti-cancer in the body. Conclusion: The promising anticancer effects mediated by adenosine receptor ligands put them in the forefront as new drug candidates. The present compilation can be worthy to medicinal chemists, pharmacologists, biochemists and other researchers focusing on the putative anticancer activity of adenosine receptor ligands.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 30
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Ribonucleotide reductase: A critical enzyme for cancer chemotherapy and antiviral agents (2007)
Another Publication in an International Scientific Journal
Nuno M F S A Cerqueira; Pedro A Fernandes; Maria J Ramos
Recent Patents on Proteasome Inhibitors of Natural Origin (2017)
Another Publication in an International Scientific Journal
da Silva, DC; Paula B Andrade; Ribeiro, V; Patricia Valentao; David M Pereira
Modulation of Proteostasis and Proteolytic Pathways as an Anti-Cancer Strategy (2017)
Another Publication in an International Scientific Journal
David M Pereira
Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies (2012)
Another Publication in an International Scientific Journal
de Mello, RA; Costa, BM; Reis, RM; Hespanhol V
Aryl- and Heteroaryl-Thiosemicarbazone Derivatives and Their Metal Complexes: A Pharmacological Template (2013)
Another Publication in an International Scientific Journal
Narayana S H N Moorthy; Nuno M F S A Cerqueira; Maria J Ramos; Pedro A Fernandes

See all (6)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-06 at 22:54:52 | Privacy Policy | Personal Data Protection Policy | Whistleblowing